EMG for Uterotonic Efficiency Estimation (EMGPHP)

Uterine Electromyography for Estimation of Uterotonic Efficiency for Postpartum Hemorrhage Prevention

Studies found conflicting results on efficacy of uterotonic agents used to prevent and treat uterine atony, the most common cause of postpartum hemorrhage. Uterine EMG can be used to objectively assess myometrial contractility and, consequently, efficacy of different uterotonics.

The investigators are planning a single-center, randomized, open-label trial to compare uterine EMG parameters in women receiving oxytocin vs. those receiving carbetocin after cesarean delivery.

Study Overview

• Status: Completed
• Conditions: Postpartum Hemorrhage
• Intervention / Treatment: Drug: Carbetocin; Drug: Oxytocin

Detailed Description

RATIONALE

Postpartum hemorrhage is the leading cause of maternal mortality worldwide. In the Western world the estimated risk of life threatening postpartum hemorrhage is 2 on 1000 births. Most frequently (up to 90% of cases of postpartum hemorrhage) it is a consequence of uterine atony or inappropriate uterine contraction. In clinical practice preventing postpartum hemorrhage is key and routinely, different prophylactic uterotonic drugs are used. The first-line recommended drug for postpartum hemorrhage prevention is oxytocin. However, a recent Cochrane meta-analysis concluded that the most effective drugs (compared to oxytocin) to prevent postpartum hemorrhage of 500 ml or more are ergometrine with oxytocin, misoprostol with oxytocin and carbetocin.

Carbetocin is a synthetic heat-stable analogue of oxytocin, with a longer half-life. It shares the same mechanism of action and the same side-effects as oxytocin. The recommended dose of carbetocin is 100 μg, which is equivalent to 10 μg (5 IU) of oxytocin. In the WHO carbetocin multicenter, double-blind, randomized trial, the intramuscular administration of 100 μg of heat-stable carbetocin was discovered to be noninferior to the administration of 10 IU of oxytocin for the prevention of postpartum hemorrhage after vaginal birth. Some studies have found carbetocin to be an effective prophylactic agent with a favourable side effect profile for the third stage of labour in caesarean sections, reducing the use of additional uterotonic agents, blood and recovery time. Moreover, carbetocin was found to be effective in reducing the need for additional uterotonic use and postpartum blood transfusion in women at increased risk of postpartum hemorrhage undergoing cesarean delivery. In one study, carbetocin was also found to be more effective than oxytocin in preventing postpartum hemorrhage in twin pregnancies delivered by cesarean section.

Uterine contractions in pregnancy, labour and postpartum can be detected using electromyography. Myometrial contractility can be objectively and non-invasively assessed in vivo by monitoring uterine electromyography (EMG), as uterine contractions are the result of the electrical activity generated and propagated in the myometrium.

To our knowledge, no study has reported oxytocin or carbetocin effects using postpartum electromyography.

OBJECTIVE The objective of the study is to compare efficacy and objectively quantify the effect of carbetocin (Pabal ®) with electromyography compared to the standard uterotonic oxytocin (Syntocinon ®) for postpartum hemorrhage prevention.

METHODS Single-center, randomized, open-label trial.

After signed informed consent, the cesarean section will be performed. All the patients will receive 5 IU of oxytocin bolus and a single oxytocin infusion (10 IU). Subsequently patients will be transferred to high dependency unit and allocated randomly into one of two groups:

1. Carbetocin group Patients will receive a single dose of carbetocin 100 mcg (Pabal ®). An electromyogram of the uterus will be performed and a blood sample will be obtained. After 2-3 hours another electromyogram will follow, as well as a visual and quantified estimation of blood loss.
2. Oxytocin group Patients will receive 5 IU of oxytocin (Syntocinon ®) as a 250 ml 0.9% NaCl infusion. An electromyogram of the uterus will be performed and a blood sample will be obtained. After 2-3 hours another electromyogram will follow, as well as a visual and quantified estimation of blood loss.

Another blood sample will be routinely obtained 24 hours after the caesarean section.

Statistical analysis

From previous EMG studies, there has been reported difference in means of EMG PS peak frequency in labor vs. non-labor patients of (0.56 - 0.44 = 0.12 Hz), and a standard deviation of 0.15 Hz. Using power of 0.80, and an α - 0.05, with t-test, gives a desired sample size of 26 per group minimum.

All data will be analyzed according to a pre-established statistical plan. Statistical analyses will be performed with SPSS software (version 24.0; IBM Corporation, Armonk, New York).

Data will be entered as numerical or categorical, as appropriate. Shapiro-Wilk test will be used to assess normality of distribution. Parametric statistics will be carried out for normally distributed variables; for non-normal distribution, nonparametric statistics will be used. Data with normal distribution will be described using minimum, maximum and mean with standard deviation. Data with non-normal distribution will be shown using minimum, maximum, median, and interquartile range (IQR). Comparisons will be carried out between the study groups using independent Student's t test or Mann-Whitney U test for continuous and with Chi-square test for categorical variables.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Slovenia
  • Ljubljana, Slovenia
    • UMC Ljubljana

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 48 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Patients with singleton pregnancies at term ( ≥37 weeks of pregnancy) scheduled for elective cesarean section after one previous cesarean section.

Exclusion Criteria:

• Contraindications for any of the study drugs.
• Anaemia Hb <100g
• History of postpartum hemorrhage
• Uterine fibroids
• Blood clotting disorder
• Placental disorder ( Placenta previa, placenta accreta)
• Preeclampsia
• Renal, cardiac or hepatic dysfunction.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: carbetocin; Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.	Drug: Carbetocin; Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
Active Comparator: oxytocin; Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.	Drug: Oxytocin; Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Power density spectrum peak frequency of uterine EMG bursts	Change in Power density spectrum (PDS) peak frequency of uterine EMG bursts between EMG at admission and 2-3 hours after treatment	within 3 hours from starting treatments

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Power density spectrum peak amplitude of uterine EMG bursts	Change in Power density spectrum (PDS) peak amplitude of uterine EMG bursts between EMG at admission and 2-3 hours after treatment.	within 3 hours from starting treatments
Frequency and duration of uterine EMG bursts	Change in frequency and duration of uterine EMG bursts between EMG at admission and 2-3 hours after treatment.	within 3 hours from starting treatments
Propagation velocity of uterine EMG signals	Propagation velocity of uterine EMG signals between EMG at admission and 2-3 hours after treatment.	within 3 hours from starting treatments
Power density spectrum integral of uterine EMG bursts	Power density spectrum (PDS) integral of uterine EMG bursts between EMG at admission and 2-3 hours after treatment.	within 3 hours from starting treatments
Change in hematocrit	Change in hematocrit between admission to high dependency unit and 24 hours after cesarean delivery.	within 24 hours after delivery
Change in hemoglobin	Change in hemoglobin between admission to high dependency unit and 24 hours after cesarean delivery.	within 24 hours after delivery
Quantified blood loss	Blood loss during treatments (from admission to the high dependency unit to EMG measurements after 2-3 hours) will be weighted.	within 3 hours from starting treatments

Collaborators and Investigators

• Sponsor: University Medical Centre Ljubljana
• Investigators: Study Chair: Miha Lucovnik, MD,PhD, UMCL

Study record dates

Study Major Dates

• Study Start (Actual): September 13, 2020
• Primary Completion (Actual): January 31, 2022
• Study Completion (Actual): January 31, 2022

Study Registration Dates

• First Submitted: December 12, 2019
• First Submitted That Met QC Criteria: December 14, 2019
• First Posted (Actual): December 17, 2019

Study Record Updates

• Last Update Posted (Actual): June 27, 2022
• Last Update Submitted That Met QC Criteria: June 24, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Keywords: postpartum hemorrhage; electohysterography; uterine electromyography
• Additional Relevant MeSH Terms: Pathologic Processes; Pregnancy Complications; Obstetric Labor Complications; Puerperal Disorders; Uterine Hemorrhage; Hemorrhage; Postpartum Hemorrhage; Physiological Effects of Drugs; Reproductive Control Agents; Oxytocics; Oxytocin; Carbetocin
• Other Study ID Numbers: 0120-398/2019/7

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No